Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CETUXIMAB Cause Multiple organ dysfunction syndrome? 48 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 48 reports of Multiple organ dysfunction syndrome have been filed in association with CETUXIMAB (ERBITUX). This represents 0.3% of all adverse event reports for CETUXIMAB.

48
Reports of Multiple organ dysfunction syndrome with CETUXIMAB
0.3%
of all CETUXIMAB reports
45
Deaths
24
Hospitalizations

How Dangerous Is Multiple organ dysfunction syndrome From CETUXIMAB?

Of the 48 reports, 45 (93.8%) resulted in death, 24 (50.0%) required hospitalization, and 10 (20.8%) were considered life-threatening.

Is Multiple organ dysfunction syndrome Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CETUXIMAB. However, 48 reports have been filed with the FAERS database.

What Other Side Effects Does CETUXIMAB Cause?

Off label use (1,549) Rash (883) Diarrhoea (874) Neutropenia (744) Nausea (663) Malignant neoplasm progression (662) Dyspnoea (542) Decreased appetite (541) Vomiting (533) Death (518)

What Other Drugs Cause Multiple organ dysfunction syndrome?

TACROLIMUS (1,847) CYCLOPHOSPHAMIDE (1,597) MYCOPHENOLATE MOFETIL (1,566) PREDNISONE (1,525) DEXAMETHASONE (1,355) METHOTREXATE (1,317) METHYLPREDNISOLONE (1,278) RITUXIMAB (1,188) PREDNISOLONE (1,154) CYCLOSPORINE (933)

Which CETUXIMAB Alternatives Have Lower Multiple organ dysfunction syndrome Risk?

CETUXIMAB vs CETYLPYRIDINIUM CETUXIMAB vs CEVIMELINE CETUXIMAB vs CHAMPIX CETUXIMAB vs CHANTIX CETUXIMAB vs CHENODIOL

Related Pages

CETUXIMAB Full Profile All Multiple organ dysfunction syndrome Reports All Drugs Causing Multiple organ dysfunction syndrome CETUXIMAB Demographics